Company Filing History:
2 out of 1,744 
2 out of 124 
1 out of 5,089 
Years Active: 2022-2024
Title: Célia Cintas: Innovator in Cancer Research
Introduction
Célia Cintas is a prominent inventor based in Toulouse, France. He has made significant contributions to the field of cancer research, particularly in understanding the PI3K signaling pathway. With a total of 2 patents, his work focuses on developing innovative strategies for predicting sensitivity to cancer treatments.
Latest Patents
Célia Cintas's latest patents include a marker for predicting sensitivity to PI3K inhibitors. This invention addresses the challenge of heterogeneity in PI3K expression patterns in tumor samples. By identifying a specific phosphopeptide, characterized by the amino acid sequence PGPSDHQSQEASQFER, the invention provides a method to better select PI3K-targeting drugs. His second patent involves a combination treatment for pancreatic cancer, where he mapped differential isoform-specific downstream signaling in response to selective inhibition. This research has led to the conclusion that combined inhibition of p110α and p110γ is the most effective strategy for treating pancreatic cancer patients.
Career Highlights
Célia Cintas has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paul Sabatier (Toulouse III). His research has been pivotal in advancing the understanding of cancer biology and treatment options.
Collaborations
He has collaborated with notable coworkers, including Julie Guillermet-Guibert and Thibaut Douche, contributing to the success of his research endeavors.
Conclusion
Célia Cintas is a key figure in cancer research, with innovative patents that aim to improve treatment strategies for patients. His work continues to influence the field and offers hope for more effective cancer therapies.